Can simplified antiretroviral drug combination therapies resist resistance?

AIDS. 2022 Sep 1;36(11):1597-1598. doi: 10.1097/QAD.0000000000003308.

Authors

Brian Conway¹, Bluma G Brenner^{2

3}

Affiliations

¹ Vancouver Infectious Diseases Centre, Vacouver, BC; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC.
² Lady Davis Institute of Medical Research, Department of Microbiology and Immunology.
³ Department of Medicine (Surgery and Infectious Disease), McGill University, Montreal, QC, Canada.

PMID: 35979831
DOI: 10.1097/QAD.0000000000003308

No abstract available

MeSH terms

Anti-HIV Agents* / therapeutic use
Anti-Retroviral Agents / therapeutic use
Drug Combinations
Drug Resistance, Viral
Drug Therapy, Combination
HIV Infections* / drug therapy
HIV Protease Inhibitors* / therapeutic use
Humans

Substances

Anti-HIV Agents
Anti-Retroviral Agents
Drug Combinations
HIV Protease Inhibitors